

1 **TITLE:** CoViD-19 rRT-PCR Testing Capacity in Ghana; Indications of Preparedness for Marburg
2 virus Outbreak?

3
4 Eric NY Nyarko^{1*}, Justice Kumi², Emmanuel K Ofori¹, Richmond O. Ateko¹, Michael Appiah³,
5 Afua B. Adjeri¹, Derrick N.D. Dodoo⁴, Broderick Yeboah Amoah⁵, Sandra ANA Crabbe¹, Ebenezer
6 K Amakye⁶, Seth D Amanquah¹, Christian Obirikorang^{7,8}, Henry Asare-Anane¹

7 ¹Department of Chemical Pathology, University of Ghana Medical School, University of Ghana

8 ²Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana.

9 ³Department of Medical Laboratory Technology, Accra Technical University

10 ⁴Department of Medical Laboratory Science, Baldwin University College

11 ⁵Department of Medical Laboratory Science, School of Biomedical and Allied Health Sciences,
12 College of Health Sciences, University of Ghana.

13 ⁶ Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, University for
14 Development Studies

15 ⁷Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah
16 University of Science and Technology, Ghana

17 ⁸Global Health and Infectious Diseases Group, Kumasi Centre for Collaborative Research, Ghana

18

19

20 ***Corresponding author**

21 Eric NY Nyarko

22 Department of Chemical Pathology,

23 University of Ghana Medical School,

24 University of Ghana, Ghana

25 cynyarko@ug.edu.gh

26

27 **Abstract**

28 **Introduction:** Ghana, as of July 2022, has had 168,350 Real-Time Reverse Transcription-
29 Polymerase Chain Reaction (rRT-PCR)-confirmed cases of CoViD-19 infections and 1,458 deaths.
30 Besides, 2 cases of Marburg virus diseases (MVD) were confirmed in the country within the same

31 month. Both CoViD-19 and MVD require rRT-PCR for diagnosis, however, rRT-PCR facilities are
32 scarce in Ghana – especially, hitherto, the CoViD-19 pandemic. The objectives of this study were to
33 assess the current testing capacity of CoViD-19 rRT-PCR in Ghana, and to make some
34 recommendations in case of an MVD outbreak, or recurrence of the CoViD-19 pandemic.

35 **Methods:** The study was cross-sectional. Questionnaires were administered to 100 health
36 professionals actively involved in the testing cycle of CoViD-19 across rRT-PCR testing institutions.
37 Responses with regards to CoViD-19 rRT-PCR testing, biosafety, and relationship with Surveillance
38 Outbreak Response Management and Analysis System (SORMAS), PanaBios and Zipline, were
39 obtained for 2020-through-2022. The responses were analyzed with Microsoft Excel office-365 and
40 SPSS v.23.

41 **Results:** Thirty-five (35) of the 53 testing institutions were in the Greater Accra Region, but none in
42 seven (7) regions of the country. Many (49%) were privately owned. Nine (9) different professionals
43 were involved in rRT-PCR testing. The testing institutions increased from 2 (in March 2020) to 53
44 by June-ending 2022, and most (90%) had Biosafety Cabinet class II (BSCII). PPEs were inadequate
45 between march and June, 2020 (25%), but enough (100%) by June 2022. Zipline, SORMAS, and
46 PanaBios, respectively, saw transactions from 28%, 81%, and 77% of the institutions.

47 **Conclusion:** Ghana is adequately resourced for recurrence of CoViD-19, or any MVD outbreak, in
48 terms of diagnosis with rRT-PCR. However, the country needs redistribution of these testing
49 resources, expand the services of Zipline and SORMAS, satisfy additional biosafety requirements for
50 MVD testing and equip over 180 GeneXpert facilities to help in accessible and affordable testing.

51 **KEYWORDS:** CoViD-19, rRT-PCR, Testing, BSC, SORMAS, Zipline, Marburg virus, Ghana

52

53 **Introduction**

54 The CoViD-19 pandemic has infected more than 574 million of the world's human population, with
55 a death rate of 6.3 million (1.1 %) as of 31st July, 2022.(1) In Ghana, there has been 168,350 Real-
56 Time Reverse Transcription-Polymerase Chain Reaction (rRT-PCR) confirmed cases with 1,458
57 deaths (0.86%).(2) At the peak of the pandemic, especially within the 2nd and 3rd quarters of 2020,
58 the importance of rRT-PCR testing to clinical management, contact tracing, isolation of infected
59 persons and quarantine of same, were extremely important. Countries such as Germany and North

60 Korea, were able to manage the CoViD-19 pandemic effectively, because they were able to identify
61 and organize their testing capacity earlier.(3) In Ghana, there was a scarcity of nucleic acid
62 amplification tests (NAAT) infrastructure, particularly rRT-PCR equipment, and biosafety cabinets
63 (BSC) class II, capable of containing class 2 and 3 dangerous viruses, making testing within
64 appropriate turn-around times (TAT) nearly impossible

65 Currently, Ghana is within the peak and post- pandemic phases, and the demand for PCR testing
66 may continuously decline, despite the possible widespread availability of CoViD-19 PCR testing (i.e.
67 September 2022). Moreover, on the 1st of July, 2022, two (2) cases of Marburg virus (MV) infections
68 resulting in Marburg virus diseases (MVD), were confirmed in the Ashanti region in Ghana.(4)
69 Marburg virus diseases is a highly infectious disease that causes haemorrhagic fever.(5) The gold
70 standard for diagnosis require rRT-PCR as the SARS-CoV-2 virus which causes the CoViD-19
71 infectious disease. However, blood sample is required and occasionally buccal, nasopharyngeal or
72 oropharyngeal samples - required for CoViD-19.(5) Though they have similar early stage clinical
73 presentations,(6), MVD is haemorrhagic, has a high case fatality rate(CFR) averaging 50%
74 (compared with <5.0% for CoViD-19) . Marburg virus diseases has no specific antiviral agent, unlike
75 CoViD-19, it has no vaccine, and requires Biosafety cabinet class III (BSCIII) during testing.(5–7)
76 This study was done to assess the CoViD-19 pandemic’s testing response infrastructure - including
77 rRT-PCR, Sample transport, Health and Laboratory Information/Management Systems (HLIMS);
78 and Biosafety equipment - build-up (or capacity) so far in Ghana, in case of post-peak CoViD-19
79 recurrent or MVD outbreak. The most popular HLIMS employed in this pandemic was the
80 SORMAS and transportation of samples outside major suburbs, towns and villages were mostly
81 done by a drone service company called Zipline. Zipline played a significant role in the management
82 of the pandemic – especially when the pandemic was at its peak. These include transport of samples
83 between sample collection and testing sites, and delivery of pharmaceutical and other medical
84 supplies from its 6 main stations. These stations were the Omenako, Mpanya and Anum in the
85 Eastern Region, Vobsi in the North East region, Sefwi Wiawso in Western North and Kete Krachi
86 in the Oti region.

87 **Methods**

88 The study design was a cross-sectional survey conducted across the 16 regions of Ghana between
89 May and July 2022. Questionnaire was initially prepared and reviewed by 10 different professionals

90 who were actively involved in the entire testing cycle, during the pandemic. The final structured
91 questionnaire was administered to 100 health professionals who are actively involved in different
92 aspects of the CoViD-19 pandemic (especially in testing) across 53 CoViD-19 rRT-PCR registered
93 institutions, consisting of 58 centres (ie 3 of the institutions had 2 or 3 testing centers) in Ghana.
94 Seventy-two (72) of the health professionals who were able to respond to at least 21 (75%) of the 28
95 questions relevant to the objectives of the study were included in the data analysis. The response rate
96 (or ‘better’ adequate response rate) was 72%. The respondents included Medical Laboratory
97 Scientists (MLS), Research Scientists, Laboratory Technologists and Technicians, Microbiologists,
98 Fulfilment Operations Professionals (FOP), Laboratory Physicians, Lecturers, Molecular Biologists
99 and Veterinary Officers. Others included a Data Entry Clerk, and a PCR Technician. Responses to
100 questions such as the location of the testing facility, rRT-PCR equipment in-use, date of
101 commencement of rRT-PCR testing, biosafety, costs of reagents and tests, turn-around-times (TAT)
102 of tests, the average number of tests per day, transactions with Surveillance Outbreak Response
103 Management and Analysis System (SORMAS), PanaBios and Zipline were obtained for 2020, 2021
104 and 2022. The responses were entered into Microsoft Excel office-365 and analyzed, together with
105 SPSS v.23.(8,9)


106 ***Patient and Public Involvement (PPI)***

107 This study did not include patients, neither did it collect health or medical data from the participants.


108

109 **Results**

110 Thirty-five (66%) of the 53 rRT-PCR testing institutions were found in the Greater Accra Region,
111 5(9%) in the Ashanti, 3 (5%) in western, 2(4%) in each of Eastern, Northern, Savannah and Upper
112 East; while Oti and Volta had 1(2%) each (**Figure 1a**). None was found in Ahafo, Brong Ahafo,
113 Bono East, Central, North-East, Upper West, and Western North regions of the country. Many, 26
114 (49%) of the institutions are privately owned, 21 (40%) are publicly owned, 5 (9%) are public-
115 private-partnerships (PPP) and 1 (2%) is a non-governmental organization (an NGO) owned
116 (**Figure 2**).




117
 118 **Figure 1a : Distribution of rRT-PCR in Ghana without most of the GeneXpert Infrastructure, and Figure 1b :**
 119 **Distribution of rRT-PCR in Ghana upon addition of the GeneXpert Infrastructure A: Ahafo, As: Ashanti, BA:**
 120 **Brong Ahafo, BE: Bono East, C:Central, E:Eastern,GA:Greater Accra, N:Northern, O:Oti,**
 121 **S:Savannah,UE:Upper East, UW: Upper West, V:Volta, W: Western, and WN: Western north regions. NB:17,**
 122 **9% are distributed either in Teaching Hospitals, Research Institutions or Islands**
 123



124
 125 **Figure 2: Type of ownership of rRT-PCR testing institutions. NGO: Non-Governmental Organization; PPP:**
 126 **Private public partnership**
 127


128 Nine (9) different professionals and experts were involved in rRT-PCR testing (i.e. bench work);
 129 including Medical Laboratory Scientists (MLS), 30 (59%), Research Scientists, 7 (13%), 3 (6%) each

130 of Laboratory Technicians and Microbiologists, 2 (4%) each of Laboratory Physicians, Molecular
 131 Biologist and Veterinary officers, and 1(2%) each of PCR technician and Laboratory technician
 132 (**Figure 3**). Other professionals who were involved (indirectly) in the testing cycle (and were
 133 included in the study) were 2 fulfilment operation professionals (FOP) from Zipline and a data entry
 134 clerk from SORMAS.



135
 136 **Figure 3: Categories of Professional expertise involved in rRT-PCR direct testing (bench work)**


137 The number of rRT-PCR testing institutions increased from 2 in march 2020 to 35 by October
 138 2020, 40 by February, 2021; 48 by June 2021; 51 by October 2021 and 53 by June 2022 (**Figure 4**).



139
 140 **Figure 4: Evolution of the number of rRT-PCR testing institutions from March 2020 to June 2022**

141
 142 Many (32%) of the 20 rRT-PCR equipment brands were either Sansure MA-6000 RT PCR or Bio-
 143 Rad CFX 96 DX RT PCR. Three (3) of the institutions commenced testing in mid-to-ending of

144 March 2020. The number increased to 35 by October 2020, 40 by February, 2021; 48 by June 2021;
145 51 by October 2021 and 53 by June 2022. There has been no new testing institution up to July 2022.
146 Twenty-seven, 48 (90%) of 53 testing institutions had Biosafety cabinet class II (BSCII), 3(6%) had
147 BSC III, and 2 (4%) had glove boxes – which are essentially BSC III (**Figure 5**).



148 **Figure 5: Number of each of Biosafety Cabinet (BSC) classes available in the rRT-PCR testing laboratories**
149 There were 25%, 96% and 100% of personal protective equipment (PPE) adequacy in 2020, 2021
150 and 2022 respectively. The average cost of reagents and other consumables per test, and the cost of
151 tests to patients have decreased from GHC 180(\$23) (in June 2020) to GHC 112(\$14) (June 30,
152 2022) and GHC 348(\$45) (in June 2020) to GHC 314(\$40) (by June 30, 2022) respectively. Turn-
153 around-time (TAT) for patients' test reports decreased from an average of 26 hours in June 2020 to
154 16 hours in 2021 and 19 hours by June 30, 2022. The average number of tests done by each
155 laboratory per day within the same periods were 388, 558 and 289 respectively. The institutions that
156 had some activity or transactions with Zipline, SORMAS and PanaBios were 28%, 81% and 77%
157 respectively. Eleven, 11(21%) of those with some transactions with Zipline received samples via
158 them, 3 (5%) both received and dispatched samples via Zipline, and 1(2%) only dispatched samples
159 through Zipline. Thirty-eight, 38(72%) of the institutions (all in the Greater Accra and Ashanti
160 Regions) had no dealings with Zipline.

162

163

164

165 **Discussions**

166 This study aimed to determine CoViD-19 rRT-PCR testing capacity in Ghana from March 2020 to
167 July 2022, and to make some recommendations, which might help in dealing with other outbreaks
168 such as the haemorrhagic Marburg Virus Disease (MVD) – in terms of testing. Ghana is (currently)
169 adequately resourced for possible recurrence of CoViD-19 or Marburg virus (MV) outbreak in terms
170 of rRT-PCR testing, however, there will be a need for redistribution of the available resources and
171 increasing of the safety materials and equipment such as PPEs and BSCs class III across the 16
172 regions, to achieve success in case of such outbreak. This must be done, considering population
173 density of each region vis-à-vis demand and supply forces. In March 2020, when Ghana recorded its
174 first 2 cases, rRT-PCR testing was the most important requirement for the identification of infected
175 persons, to contact tracing, isolating and quarantining, and to clinically design management strategies
176 for infected persons.(10) Evolution of the number of testing institutions was examined in this
177 study. Before March 2020, the Noguchi Memorial Institute for Medical Research (NMIMR), the
178 National Public Health Reference Laboratory (NPHRL), and the Kumasi Centre for Collaborative
179 Research (KCCR) were ‘adequately resourced’ to test for CoViD-19 virus using the rRT-PCR. By
180 June, 2020, there were 20 CoViD-19 PCR testing institutions, mostly concentrated within the Accra
181 metropolis of the Greater Accra Region. These had an equal private-to-public ownership ratio - with
182 a few scattered in other major cities such as Takoradi in the Western Region and Kumasi in the
183 Ashanti Region.

184 The rate with which Ghana developed this testing capacity is remarkable (**Figure 4**), and it was
185 comparable to what had been reported in few African countries. (11) These 53 institutions exclude
186 the majority of Ghana Health Service (GHS) and other institutions with Cepheid GeneXpert
187 infrastructure – capable of CoViD-19 rRT-PCR testing. There are over 130 GeneXpert devices in
188 facilities across the country,(12) often used for *Mycobacterium tuberculosis* testing.(13) This study found
189 the availability of the rRT-PCR model equipment in only 9 of the 16 regions. There were none in
190 the Ahafo, Brong Ahafo, Bono East, Central, North-East, Upper West, and Western North regions
191 of the country. Centralizing the testing facilities to few locations negatively affects the management
192 of any pandemic, as has been experienced in countries like Ecuador.(14) Hence, the resourcing of
193 the GeneXperts CoViD-19 rRT-PCR specific cartridges and other biosafety requirements, will
194 make available more than 180 facilities able to do the rRT-PCR required for CoViD-19 or MVD
195 diagnosis. Such provisions will result in at least 3(2%) rRT-PCR facilities in the Ahafo region,

23(12%) in Ashanti, 7(4%) in Bono East, 5(3%) each in Brong Ahafo, Savannah and Western
North; 10(5%) in Central, 21(11%) in Eastern, 46(25%) in Greater Accra, and 6(3%) each in
Northern and Oti (**Figure 1b**). Others will include, 8(4%) in Upper East, 4(2%) in Upper West,
12(6%) in Volta, and 8(4%) in Western. Besides, there will be 17 (9%) of these testing devices
available in Ghanaian research institutions, teaching hospitals, public health reference laboratories
and at deprived and ‘difficult-to-reach’ locations. This will help build the capacity of local
professionals through training, reduce testing cost, and reduce the TAT. It will also increase
accessibility and rapid response to CoViD-19 or other viral outbreaks such as the Marburg virus -
which has a higher Case fatality rate (CFR) (of 50%), compared to CoViD-19.

At the genesis of the pandemic in 2020, PPEs were scarce – even for health professionals involved
in patient contact, sample collection and testing.(15) However, by June 2022, PPEs were adequate
for these purposes (i.e. 25% adequacy of PPEs in 2020 compared to 100% in 2022). In case of a
Marburg Virus (MV) outbreak, safe sample collection, transport and testing for these risk group 4
pathogens would require all PPEs for CoViD-19 including (K)N95 Medical masks, eye protection
(goggles), gloves, disposable gowns, and face shields. In addition, there would be a need for
(personal) positive pressure suits or additional protection over laboratory clothing, such as solid-
front gowns with tight-fitting wrists, two pairs of latex (preferably rubber) gloves, and an approved
particulate respirator (e.g., N95 or higher), and impermeable cleanable footwear with its-
impermeable (disposable) covers.(16) Also, there would be the need for containment level 4 facilities
with a minimum of BSC class III for most laboratory procedures, and from this study we have just a
few of such BSCs, but are mostly concentrated in the Greater Accra and Ashanti regions. Thus,
more of BSC class III are required. This study found a reduction in the average cost of reagents and
consumables per test, and a decline in the number and cost of tests from June 2020, through to June
2022. These reductions could be as a result of increases in the number of the testing service
outlets/institutions, opening of the country’s border for imports (there by increasing the supply side
of resources), vaccination against the virus, reduced public restrictions, and the country being in the
post-peak stage of the pandemic – all of which affect the supply and demand forces for the rRT-
PCR testing. Similar findings have been reported in some African countries, including South Africa
and Nigeria.(17,18)

All the participants from the public testing facilities couldn’t tell the cost of the PCR reagents and
consumables per test, but most from the commercial private and public-private-partnered (PPP)

227 institutions were able to provide such costs. The average cost of testing (reagents and other direct
228 consumables) declined by 38% from June 2020, and 20% from June 2021. These declines in average
229 cost of testing, and that of the test prices could be due to equipment placement, and
230 reagent/consumable high-purchase services expanded by the players (in the industry) within the
231 mid-2021. Other factors such as the increasing in the number of suppliers, may have contributed to
232 these trends in prices. The average cost of tests within the same period decreased from GHC 349
233 (\$45) in 2020/21 to GHC 314 (\$40) by June 2022. It could be said from these, that an average of
234 GHC 168 (\$22) (i.e.93%), GHC198 (\$25) (130%), and GHC202(\$26) (180%) direct-gross profits
235 were made per test each year (ending) June 2020, June 2021 and June 2022 respectively. These
236 findings have been collaborated by other reports from other African countries.(17,18) The average
237 number of CoViD-19 PCR tests done by each laboratory increased from 388/day (in 2020) to
238 558/day (in 2021) and has declined to 289/day by June 2022. These decreases in costs and number
239 of tests (especially from the 2nd quarter of 2022) could be due to availability and increased access to
240 vaccines, reduced infection prevalence and incidence of the virus, acquisition of immunity and likely
241 reduced virulence of the virus (at the post-peak phase). The reduction in, and non-patronage of the
242 Zipline services in the Greater Accra region could be due to the proximity of patients to many
243 testing institutions within the region. It is also significant to note that, the North East region, which
244 lacks a CoViD-19 rRT-PCR testing institution could dispatch its samples to a nearby region with
245 these drones, since there is a drone service centre at Vobsi in the West Mamprusi Municipality of the
246 region.

247 In a pandemic like CoViD-19, testing must be linked to public and community health information
248 management systems to help in decisions on surveillance, patient management, contact tracing, and
249 further testing. By June 30th 2022, most, 43 (81%) of the testing institutions were in-putting their
250 CoViD-19 laboratory data on the SORMAS platform to help monitor and survey some
251 epidemiological characteristics of the CoViD-19 pandemic. This activity also helped in the
252 management of the pandemic, as decisions were mostly based on reliable data within Ghana and by
253 extension, West Africa. Besides, most, 41, (77%) of the institutions had PanaBios certification and
254 validation, which gave some international permissions to travelers and states with regards to their
255 CoViD-19 infectious status, through the PanaBios Trusted Travel platform.

256 This study strongly recommends that, all testing institutions dealing with pathogens of public health
257 importance, concern, epidemic or pandemics, henceforth, must compulsorily be on surveillance

258 platforms such as the SORMAS to help in informed surveillance and monitoring. Also, the number
259 of locations and services of Zipline, especially in the seven regions which are currently without
260 actual rRT PCR testing facilities need to be expanded. When this is done widely, the country could
261 limit the number of testing institutions across the remote parts of the country – thus saving costs
262 and reducing the risk of infections that might occur due to personal(human) delivery services and
263 community fallouts. In addition to these, this transport technology may be employed for other
264 health services – such as the transport of blood products for transfusion within the Ghana health
265 system and in any infectious outbreak. Moreover, with these findings and the knowledge of CoViD-
266 19 rRT-PCR testing techniques, resourcing the GeneXpert devices and facilities with CoViD-19
267 rRT-PCR reagents (or MV reagents -in MV outbreak), consumables, PPEs and other biosafety
268 devices are recommended.

269

270 **Conclusions**

271 Through the CoViD-19 pandemic, Ghana has built adequate capacity for molecular testing and is
272 adequately resourced for recurrence of CoViD-19 or Marburg virus outbreak in terms of diagnosis
273 with rRT-PCR. However, Ghana needs redistribution of these resources, satisfy additional safety
274 requirements for Marburg virus testing and equip over 180 GeneXpert facilities with the additional
275 infrastructure and materials required for testing. There is also a need to expand the services of
276 infection control centers in case of hemorrhagic epidemic or pandemic. It is recommended that, all
277 testing institutions dealing with pathogens of public health concern, henceforth, must compulsorily
278 be on surveillance platforms such as the SORMAS to help in informed surveillance and monitoring.
279 The CoViD-19 pandemic has brought many health, social and economic challenges. However,
280 Ghana now has adequate testing capacity for diagnosis. There are now adequate PPEs, improved
281 data management, technologies for transport of health resources, and an added opportunity to
282 improve, in case of an outbreak by other viruses like the Marburg virus.

283 **Abbreviations**

284 rRT-PCR: Real-Time Reverse Transcription-Polymerase Chain Reaction

285 CoViD-19: SARS – COV-2 Disease 2019

286 MV: Marburg Virus

287 MVD: Marburg Virus Disease

288 NAAT: Nucleic acid amplification testing

289 PPS: Positive Pressure Suit

290 GHS: Ghana Health Service

291 WHO: World Health Organization

292 SORMAS: Surveillance Outbreak Response Management and Analysis System

293 TAT: Average turn-around-time per test per patient

294 CDC: Centre for Disease Control and Prevention, USA

295 BSC: Biosafety Cabinet

296 PPE: Personal Protective Equipment

297

298

299 **DECLARATIONS**

300 **Acknowledgement**

301 The authors acknowledge the efforts of the entire staff of the department of Chemical Pathology of
302 the University of Ghana Medical School, and all the professionals who took time off their busy
303 schedules to respond to our questionnaire, especially the reviewers of the questionnaire. The authors
304 are also grateful to all the participating institutions, especially those who responded to phone calls on
305 follow-ups and those who allowed them into their facilities to verify and confirm some responses.

306 **Authors' contributions**

307 ENYN was involved in conceptualization, methodology, software, supervision, validation, Writing
308 – original draft, Writing – review & editing; JK, EKO, DD, EKA, CO & HAA were involved in
309 methodology, supervision, software, data analysis, writing – original draft, writing – review & editing;
310 ROA, MA, ABA, BYA, SAC & SDA contributed in validation, writing – review & editing. All
311 authors read and approved the manuscript before submission

312 **Funding**

313 This research did not receive any specific grant from funding agencies in the public, commercial, or
314 not-for-profit sectors.

315 **Availability of data and materials**

316 The datasets used and/or analyzed during the current study are available from the corresponding
317 author on reasonable request.

318 **Ethical Considerations and consent to participate**

319 Not Applicable

320 **Competing interests**

321 The authors declare that they have no competing interests.

322 **Consent for publication**

323 Not applicable.

324

325 **Figure Legends**

326 **Figure 1a** : Distribution of rRT-PCR in Ghana without most of the GeneXpert Infrastructure, and
327 **Figure 1b** : Distribution of rRT-PCR in Ghana upon addition of the GeneXpert Infrastructure A:
328 Ahafo, As: Ashanti, BA: Brong Ahafo, BE: Bono East, C:Central, E:Eastern,GA:Greater Accra,
329 N:Northern, O:Oti, S:Savannah,UE:Upper East, UW: Upper West, V:Volta, W: Western, and WN:
330 Western north regions. **NB**: 17, 9% are distributed either in Teaching Hospitals, Research Institutions or
331 Islands

332
333 **Figure 2**: Type of ownership of rRT-PCR testing institutions. NGO: Non-Governmental
334 Organization; PPP: Private public partnership

335
336 **Figure 3**: Categories of Professional expertise involved in rRT-PCR direct testing (bench work)

337
338 **Figure 4**: Evolution of the number of rRT-PCR testing institutions from March 2020 to June 2022

339
340 **Figure 5**: Number of each of Biosafety Cabinet (BSC) classes available in the rRT-PCR testing
341 laboratories

342

343 **REFERENCES**

- 344 1. World Health Organization W. COVID-19 Weekly Epidemiological Update. World Heal
345 Organ. 2022;Edition 10(August).
- 346 2. GHS GHS. Covid-19 Update. Covid-19 Update. 2022.
- 347 3. Acheampong Godfred, Michael Owusu, Bernard Nkrumah, Priscilla ObengBoadi, David A.
348 Opare, David J. Sambian PA& CW. Laboratory capacity in COVID-19 diagnosis and the
349 need to enhance molecular testing in Ghana Laboratory capacity in COVID-19 diagnosis and
350 the need to enhance molecular. Glob Secur Heal Sci Policy [Internet]. 2021;6(1):10–7.
351 Available from: <https://doi.org/10.1080/23779497.2021.1908157>
- 352 4. World Health Organization W. Ghana reports first-ever suspected cases of Marburg virus
353 disease. 2022.
- 354 5. CDC, Diseases NC for E and ZI, Division of High-Consequence Pathogens and Pathology
355 (DHCPP) C. Marburg Hemorrhagic Fever. CDC Factsheet. 2022.
- 356 6. Osaretin C, Emeka F, Mohanan P, Salma M, Saleem A, Ahmed U, et al. Marburg virus
357 disease outbreak amidst COVID-19 in the Republic of Guinea: A point of contention for the
358 fragile health system? Clin Epidemiol Glob Heal. 2020;13 (2022)(January):2020–3.
- 359 7. CDC. Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition | CDC
360 Laboratory Portal | CDC. US Dep Heal Hum Serv [Internet]. 2020; Available from:
361 <https://www.cdc.gov/labs/BMBL.html>0Ahttps://www.cdc.gov/labs/BMBL.html?CDC_
362 AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fbiosafety%2Fpublications%2Fbmb15%2Fi
363 ndex.htm
- 364 8. Corporation M. Microsoft Office-365 Excel [Internet]. 2018. Available from:
365 <https://office.microsoft.com/excel>.
- 366 9. IBM Corp. IBM Corp SPSS version 23 [Internet]. 2022. Available from:
367 [https://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=2&sid=31c18559-0cab-41ef-](https://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=2&sid=31c18559-0cab-41ef-a9ae-3856d5d4ea8b%40sessionmgr101)
368 [a9ae-3856d5d4ea8b%40sessionmgr101](https://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=2&sid=31c18559-0cab-41ef-a9ae-3856d5d4ea8b%40sessionmgr101)
- 369 10. World Health Organizaton. Prevention, identification and management of health worker
370 infection in the context of COVID-1. WwwWhoInt [Internet]. 2020;58(12):1–4. Available

- 371 from: <https://apo.who.int/publications/i/item/10665-336265>
- 372 11. Amukele T, Spence RN. African countries established COVID-19 testing in one month:
373 Here's how they did it. *Afr J Lab Med*. 2021;10(1):1–6.
- 374 12. Dennis A-G. Is Ghana against the use of GeneXpert and resourcing clinical laboratories for
375 COVID-19 testing? [Internet]. 2020. Available from:
376 <https://adugyasidennis.com/index.php/2020/07/21/>
- 377 13. Aninagyei E, Ayivor-Djanie R, Attoh J, Dakorah MP, Ginko MN, Acheampong DO.
378 Molecular detection of Mycobacterium tuberculosis in blood stained sputum samples using
379 GeneXpert PCR assay. *Diagn Microbiol Infect Dis* [Internet]. 2021;100(3):115363. Available
380 from: <https://doi.org/10.1016/j.diagmicrobio.2021.115363>
- 381 14. Torres I, Sippy R, Sacoto F. Assessing critical gaps in COVID-19 testing capacity: the case of
382 delayed results in Ecuador. *BMC Public Health*. 2021;21(1):1–8.
- 383 15. Afulani PA, Gyamerah AO, Nutor JJ, Laar A, Aborigo RA, Malechi H, et al. Inadequate
384 preparedness for response to COVID-19 is associated with stress and burnout among
385 healthcare workers in Ghana. *PLoS One* [Internet]. 2021;16(4 April):1–20. Available from:
386 <http://dx.doi.org/10.1371/journal.pone.0250294>
- 387 16. World Health Organization W. Marburg virus disease. Vol. 14, Operational Support &
388 Logistics Disease Commodity Packages. 2018.
- 389 17. Donna Marrie P. private-labs-in-south-africa-voluntarily-agree-to-lower-prices-for-covid-19-
390 pcr-tests-following-investigation-by-countrys-competition-commission. *Dark Daily*.
391 2022;2003–5.
- 392 18. Kanabe M. Covid-19-lagos-announces-reduction-in-pcr-test-fees. *Premium Times Nigeria*.
393 2022;508060.
- 394